It is unfortunate that the PR was poorly written.as too many have been.

The company is moving along well, with efficacy data coming and all the appropriate communication with FDA occurring out of our sight.

Vitally important in my mind to differentiate the state of the company from the stock price.

That is why am totally divested now from Humanigen and more over invested in Cytodyn.

Just my opinion, but hand wringing over daily and hourly stock price misses the forest for the trees.